Меню
Идёт набор NCT06419777

Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes

Без фазы С лечением Gestational Diabetes Pregnancy Related

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Insulin.
Кому может быть актуально
Состояния в реестре: Gestational Diabetes, Pregnancy Related. Базовые параметры: от 18 лет · Женщины.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Strict Versus Permissive Threshold for Initiation of Pharmacotherapy in Gestational Diabetes Mellitus (GDM) With Glucometer Use - A Randomized Control Trial (START1)

Обзор

The aim of our study is to compare neonatal and maternal outcomes using different thresholds for the initiation and titration of pharmacotherapy for gestational diabetes (GDM). Our goal is to compare a strict and permissive threshold. The strict threshold is defined as two abnormal values or more over a one-week period (two fasting values elevated, two of the same post prandial values elevated, or 1 fasting and 1 post prandial value elevated), whereas the permissive threshold is defined as 50% of values elevated over 1 week (50% of overall fasting values, 50% of postprandial values, or 50% of overall values).

Подробное описание

Pregnancy is a state of insulin resistance to ensure that the growing fetus has ample nutrition. Gestational Diabetes (GDM) develops in pregnant patients with pancreatic dysfunction that leads to impairment of glucose tolerance.

Various studies have examined the benefit of treatment for GDM, including the 2005 Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) and the 2009 Landon et al randomized controlled trials. These studies found that treatment was associated with a significant reduction in newborn complications of perinatal death, shoulder dystocia, large for gestational age infants, cesarean delivery, and birth trauma. The specific threshold value for initiation and up-titration of medical therapy is unknown. Lack of evidence leads to a wide variation in clinical practice of pharmacological initiation and titration for GDM. A systematic review and meta-analysis by Caissutti in 2019 analyzed criteria for initiating pharmacotherapy for GDM and noted the following: 12 of 15 trials initiated pharmacotherapy after 1-2 abnormal values over 1-2 weeks, 2 studies initiated pharmacotherapy after 50% of overall values were abnormal, and 1 study initiated pharmacotherapy after 30% of overall values were abnormal. However, there have been no randomized controlled trials of head-to-head comparison of different thresholds.

The aim of our study is to compare neonatal and maternal outcomes using different thresholds for the initiation and titration of pharmacotherapy for gestational diabetes. Our goal is to compare a strict and relaxed threshold. The strict threshold is defined as two abnormal values or more over a one week period (two fasting values elevated, two of the same post prandial values elevated, or 1 fasting and 1 post prandial value elevated), whereas the relaxed threshold is defined as 50% of values elevated over 1 week (50% of overall fasting values, 50% of postprandial values, or 50% of overall values).

Вмешательства

  • Препарат Insulin
    Insulin will be used in gestational diabetics to control blood glucose levels

Первичные конечные точки

  • Neonatal Composite Outcome [Срок оценки: First 28 days of birth]
Вторичные конечные точки (12)
  • Neonatal Outcome: Gestational Age of Birth [Срок оценки: Delivery Time]
  • Neonatal Outcome: APGAR Score [Срок оценки: At 1 minute of life and at 5 min of life]
  • Neonatal Outcome: Birthweight [Срок оценки: Delivery Time]
  • Neonatal Outcome: Brachial Plexus Injury [Срок оценки: Delivery Time]
  • Neonatal Outcome: Respiratory distress [Срок оценки: Within first 24 hours after delivery]
  • Neonatal Outcome: Admission to Neonatal intensive Care Unit [Срок оценки: From delivery to discharge from NICU]
  • Maternal Outcomes: Maternal hypoglycemia [Срок оценки: Initiation of insulin to delivery]
  • Maternal Outcomes: Shoulder Dystocia [Срок оценки: At Delivery]
  • Maternal Outcomes: Obstetric anal sphincter injury (OASIS) [Срок оценки: At Delivery]
  • Maternal Outcomes: Operative Delivery [Срок оценки: At Delivery]
  • Maternal Outcomes: Cesarean Delivery [Срок оценки: At Delivery]
  • Maternal Outcomes: Postpartum hemorrhage [Срок оценки: Within 24 hours of delivery]

Критерии участия

Критерии включения

  • Live, non-anomalous fetus
  • Literacy in English, Spanish, Mandarin, or Arabic
  • Patients are also required to provide consent, demonstrate an understanding of the purpose of the study, and agree to the study protocol.

Критерии исключения

  • <18 years at EDD
  • pre-existing diabetes or diagnosis of GDM before 24 weeks
  • multi-fetal gestation
  • known major fetal anomaly
  • known allergy to insulin
  • chronic maternal corticosteroid use
  • diagnosis of GDM based on finger sticks alone
  • patients who have contraindication to oral glucose tolerance test
  • a primary language other than English, Spanish, Mandarin, or Arabic

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Открытое
Основная цель
Лечение

Центры проведения

США · 2 центра
  • University of Rochester Medical Center — Rochester
  • Thomas Jefferson University — Philadelphia

Публикации

  • Kunarathnam V, Vadakekut ES, Mahdy H. Gestational Diabetes. 2025 Sep 15. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK545196/ PMID 31424780
  • Catalano PM, Hauguel-De Mouzon S. Is it time to revisit the Pedersen hypothesis in the face of the obesity epidemic? Am J Obstet Gynecol. 2011 Jun;204(6):479-87. doi: 10.1016/j.ajog.2010.11.039. Epub 2011 Feb 2. PMID 21288502
  • Gregory EC, Ely DM. Trends and Characteristics in Gestational Diabetes: United States, 2016-2020. Natl Vital Stat Rep. 2022 Jul;71(3):1-15. PMID 35877134
  • Metzger BE, Persson B, Lowe LP, Dyer AR, Cruickshank JK, Deerochanawong C, Halliday HL, Hennis AJ, Liley H, Ng PC, Coustan DR, Hadden DR, Hod M, Oats JJ, Trimble ER; HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcome study: neonatal glycemia. Pediatrics. 2010 Dec;126(6):e1545-52. doi: 10.1542/peds.2009-2257. Epub 2010 Nov 15. PMID 21078733
  • ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstet Gynecol. 2018 Feb;131(2):e49-e64. doi: 10.1097/AOG.0000000000002501. PMID 29370047
  • Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS; Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med. 2005 Jun 16;352(24):2477-86. doi: 10.1056/NEJMoa042973. Epub 2005 Jun 12. PMID 15951574
  • Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, Wapner RJ, Varner MW, Rouse DJ, Thorp JM Jr, Sciscione A, Catalano P, Harper M, Saade G, Lain KY, Sorokin Y, Peaceman AM, Tolosa JE, Anderson GB; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A multicenter, randomized trial of treatment for mild gestational diabete PMID 19797280
  • Hartling L, Dryden DM, Guthrie A, Muise M, Vandermeer B, Donovan L. Benefits and harms of treating gestational diabetes mellitus: a systematic review and meta-analysis for the U.S. Preventive Services Task Force and the National Institutes of Health Office of Medical Applications of Research. Ann Intern Med. 2013 Jul 16;159(2):123-9. doi: 10.7326/0003-4819-159-2-201307160-00661. PMID 23712381

Идентификаторы

NCT: NCT06419777 · iRISID-2024-2999

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗